Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma

• Verfasst von: Avivi, Irit [VerfasserIn]
• Verfasst von: Canals, C. [VerfasserIn]
• Verfasst von: Vernant, J.-P. [VerfasserIn]
• Verfasst von: Wulf, G. [VerfasserIn]
• Verfasst von: Nagler, A. [VerfasserIn]
• Verfasst von: Hermine, O. [VerfasserIn]
• Verfasst von: Petersen, E. [VerfasserIn]
• Verfasst von: Yakoub-Agha, I. [VerfasserIn]
• Verfasst von: Craddock, C. [VerfasserIn]
• Verfasst von: Schattenberg, A. [VerfasserIn]
• Verfasst von: Niederwieser, D. [VerfasserIn]
• Verfasst von: Thomson, K. [VerfasserIn]
• Verfasst von: Blaise, D. [VerfasserIn]
• Verfasst von: Attal, M. [VerfasserIn]
• Verfasst von: Pfreundschuh, M. [VerfasserIn]
• Verfasst von: Passweg, J. [VerfasserIn]
• Verfasst von: Russell, N. [VerfasserIn]
• Verfasst von: Dreger, Peter [VerfasserIn]
• Verfasst von: Sureda, A. [VerfasserIn]
• Titel: Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma
• Verf.angabe: I Avivi, C Canals, J-P Vernant, G Wulf, A Nagler, O Hermine, E Petersen, I Yakoub-Agha, C Craddock, A Schattenberg, D Niederwieser, K Thomson, D Blaise, M Attal, M Pfreundschuh, J Passweg, N Russell, P Dreger, A Sureda on behalf of the EBMT Lymphoma Working Party
• E-Jahr: 2014
• Jahr: 10 February 2014
• Umfang: 8 S.
• Fussnoten: Gesehen am 03.09.2020
• Titel Quelle: Enthalten in: Bone marrow transplantation
• Ort Quelle: London : Springer Nature, 1997
• Jahr Quelle: 2014
• Band/Heft Quelle: 49(2014), 5, Seite 671-678
• ISSN Quelle: 1476-5365
• DOI: doi:10.1038/bmt.2014.4
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1728806097

Abstract

The objective of this retrospective analysis was to compare outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who received either a matched sibling (sib) or an unrelated donor (URD) allogeneic hematopoietic cell transplantation (allo-HCT). Long-term outcome of 172 DLBCL patients receiving URD-HCT between 2000 and 2007 and reported to the European Group for Blood and Marrow Transplantation, was compared with that of 301 subjects, allografted from sib-HCT. With a median follow-up of 45 months, 3-year PFS approached 35% for both groups; overall survival (OS) was 42% for sib-HCT versus 37% for URD (NS). Multivariate analyses confirmed that donor type was not associated with differences in non-relapse mortality (NRM), relapse rate (RR), PFS or OS. Poor performance status (PS) and refractory disease adversely affected PFS and OS. Prior auto-SCT and multiple previous therapies predicted for shorter PFS. NRM was adversely affected by older age (⩾50 years), poor PS and refractory disease, and RR by time from diagnosis to allo-HCT of <36 months, prior auto-SCT, refractory disease, poor PS and in vivo T-cell depletion with alemtuzumab. This large study shows for the first time that URD-HCT is not inferior to sib-HCT, providing a reasonable therapeutic approach for DLBCL patients, having no HLA-identical sibling available.